MedPal AI (AIM:MPAL) told investors that its New Health weight-management clinic has climbed to 29th place in Eli Lilly's ranking of UK Mounjaro suppliers by volume, up from 3,048th roughly three months ago, after Eli Lilly confirmed the position directly.
The AIM-listed digital health and pharmacy group said New Health now has more than 42,500 customers, up from over 33,000 at the end of September, giving it an estimated 2.1% share of the UK's GLP-1 weight-management market based on Novo Nordisk's written evidence to the House of Commons Health and Social Care Committee, which put the total UK user base at roughly 2 million, over 90% of them private patients.
New Health is the consumer brand MedPal launched to capture GLP-1 weight-management and peptide demand, backed by a phased national marketing campaign costing roughly £1.3 million over six months.
The group said it remains on track to open an expanded GLP-1 dispensing line at its Sarus Court facility by the end of October, taking capacity there to 14,000 orders a day.
"From 3,048th to 29th in three months," said Jason Drummond, founder and chief executive, adding that repeat orders now account for more than 30% of New Health revenue, up from 22% in September, "with no acquisition cost attached."
Drummond said the company's ambition is to become a top-three UK GLP-1 provider, calling the Sarus Court expansion "only the beginning" of what the group's integrated "Health OS" platform was built to deliver.